

# Bicycle®

**\$200 Million**  
Follow-On Offering

**LEERINK **  
PARTNERS

Joint Bookrunner  
July 2023

## Leerink Partners Serves as Joint Bookrunner for Bicycle Therapeutics' (Nasdaq: BCYC) \$200.0 Million Follow-On Offering

### Key Transaction Highlights

- Confidentially marketed, and then publicly launched on July 12th post-close and priced overnight
- Well oversubscribed from both new and existing investors
- Base deal consisted of 9,411,766 ADSs, each representing one ordinary share and, in lieu of ADSs to investors that so chose, non-voting ordinary shares, each priced at \$21.25 per share.
- Priced at a 3.4% discount to last sale
- Bicycle intends to use the net proceeds of this offering to fund the continued development of its proprietary pipeline and for other research and development, as well as for general corporate purposes.
- This is Leerink Partners' 2nd bookrun offering for Bicycle Therapeutics and 34th bookrun equity offering in 2023.

If you would like to unsubscribe from this distribution, click [here](#). If you would like to unsubscribe from all Leerink Partners distributions, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

**BOSTON**  
53 State Street  
40th Floor  
Boston, MA 02109

**CHARLOTTE**  
2151 Hawkins Street  
Suite 1025  
Charlotte, NC 28203

**NASHVILLE**  
40 Burton Hills Boulevard  
Suite 200  
Nashville, TN 37215

**NEW YORK**  
1301 Avenue of the Americas  
12th Floor  
New York, NY 10019

**SAN FRANCISCO**  
255 California Street  
12th Floor  
San Francisco, CA 94111